Clinical review report: Rivaroxaban (Xarelto) Bayer Inc. : indication : in combination with 75 mg to 100 mg acetylsalicylic acid, for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease with or without peripheral artery disease

The objective of the review was to perform a systematic review of the beneficial and harmful effects of rivaroxaban 2.5 mg, in combination with acetylsalicylic acid 75 mg to 100 mg, for the prevention of stroke, myocardial infarction, and cardiovascular death and for the prevention of acute limb isc...

Full description

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH January 2019, 2019
Edition:Final (with redactions)
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:The objective of the review was to perform a systematic review of the beneficial and harmful effects of rivaroxaban 2.5 mg, in combination with acetylsalicylic acid 75 mg to 100 mg, for the prevention of stroke, myocardial infarction, and cardiovascular death and for the prevention of acute limb ischemia (ALI) and mortality in patients with coronary artery disease, with or without peripheral artery disease
Physical Description:1 PDF file (103 pages) illustrations